| Name | CMS-121 |
| Description | CMS-121, a quinolone derivative, is an orally active acetyl-CoA carboxylase 1 (ACC1) inhibitor. CMS-121 protects HT22 cells against ischemia and oxidative damage (EC50: 7 nM and 200 nM). CMS-121 shows strong neuroprotective, antioxidative, anti-inflammatory, and renoprotective activities. |
| In vitro | CMS-121 can increase acetyl-CoA in cells. CMS-121 (1 μM; 4 hours; HT22 cells) treatment also increases the phosphorylation of ACC1 at serine 79.[1]. |
| In vivo | CMS-121 preserves mitochondrial homeostasis by regulating acetyl-coenzyme A (acetyl-CoA) metabolism. CMS-121 (~20 mg/kg; p.o; daily; for 4 months; female SAMP8 mice) treatment decreases cognitive decline and metabolic and transcriptional markers of aging in the brain when administered to rapidly aging SAMP8 mice. [1]. |
| Storage | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : 55 mg/mL (171.14 mM), Sonication is recommended.
10% DMSO+40% PEG300+5% Tween 80+45% Saline : 2 mg/mL (6.22 mM), Sonication is recommended.
|
| Keywords | neuroprotective | mitochondrial | Inhibitor | inhibit | H3K9 | disease | dementia | CMS-121 | CMS 121 | antioxidative | anti-inflammatory | Alzheimer's | AcetylCoACarboxylase | Acetyl-CoA carboxylase 1 (ACC1) | Acetyl-CoA Carboxylase | AcetylCoA Carboxylase | acetylation | ACC1 | ACC, Acetyl Coenzyme A Carboxylase |
| Inhibitors Related | Alisol A | Cyhalofop-butyl | Acetyl-CoA Carboxylase-IN-1 | Firsocostat | PF-05221304 | Clethodim | Moiramide B | Clodinafop-propargyl | VY-3-135 | Quizalofop-ethyl | TOFA | Tralkoxydim |
| Related Compound Libraries | Bioactive Compound Library | Anti-Obesity Compound Library | Antioxidant Compound Library | Drug Repurposing Compound Library | Neuroprotective Compound Library | Inhibitor Library | Lipid Metabolism Compound Library | Immunology/Inflammation Compound Library | Anti-Aging Compound Library | Clinical Compound Library | Bioactive Compounds Library Max | Anti-Hypertension Compound Library |
United States
